Geron Corporation ((GERN)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Geron Corporation is conducting a Phase 3 clinical study titled ‘A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor.’ The study aims to assess the overall survival of participants with intermediate-2 or high-risk Myelofibrosis who have not responded to JAK-Inhibitor treatment, highlighting its significance in addressing unmet medical needs in this patient population.
The study tests two interventions: Imetelstat, an experimental drug administered intravenously every 21 days, and Best Available Therapy (BAT), a comparator involving non-JAK-inhibitor treatments such as hydroxyurea or thalidomide. The purpose is to determine which treatment offers better outcomes for patients with relapsed or refractory Myelofibrosis.
This interventional study is randomized with a parallel assignment model, meaning participants are randomly allocated to either the Imetelstat or BAT group. The study is open-label, indicating no masking is used, and its primary purpose is treatment-focused.
The study began on September 18, 2020, with an estimated primary completion date in 2025, and the last update was submitted on August 18, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might influence clinical practice and market dynamics.
The update on this study could significantly impact Geron Corporation’s stock performance, as positive results might enhance investor confidence and market valuation. The study’s outcome could also affect the competitive landscape, particularly for companies developing treatments for Myelofibrosis.
The study is ongoing, with further details available on the ClinicalTrials portal.